MiNK Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	3.37	19.64	38.89	2.69	0.3
Cash & Cash Equivalents	3.37	19.64	38.89	2.69	0.3
Cash Growth	-82.85%	-49.51%	1345.06%	799.94%	-
Other Current Assets	0.23	0.77	0.75	1.41	0.62
Total Current Assets	3.6	20.4	39.63	4.1	0.92
Property, Plant & Equipment	0.95	1.07	0.61	0.46	0.39
Total Long-Term Assets	0.95	1.07	0.61	0.46	0.39
Total Assets	4.55	21.47	40.24	4.56	1.31
Accounts Payable	15.07	14.9	8.94	6.67	4.63
Deferred Revenue	0	0	0	0	0.19
Other Current Liabilities	-3.67	-2.22	7.52	7.55	2.6
Total Current Liabilities	11.4	12.68	16.47	14.22	7.42
Long-Term Debt	0	0	0	43.82	26.79
Other Long-Term Liabilities	11.21	9.19	0	0.38	3.43
Total Long-Term Liabilities	11.21	9.19	0	44.21	30.22
Total Liabilities	22.61	21.87	16.47	58.43	37.64
Total Debt	0	0	0	43.82	26.79
Debt Growth	-	-	-	63.58%	-
Retained Earnings	-133.4	-110.94	-82.95	-52.74	-36.5
Comprehensive Income	-0.43	-0.29	-0.63	-1.52	-0.13
Shareholders' Equity	-18.06	-0.4	23.78	-53.87	-36.33
Net Cash / Debt	3.37	19.64	38.89	-41.13	-26.49
Net Cash / Debt Growth	-82.85%	-49.51%	-	-	-
Net Cash Per Share	0.10	0.58	1.49	-1.71	-3.06
Working Capital	-7.8	7.72	23.17	-10.13	-6.5
Book Value Per Share	-0.53	-0.01	0.91	-2.23	-4.20

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).